ADANT ONE 1 JERINGA PRECARGADA HIALURONATO SODIC 49 MG

ACTION AND DESCRIPTION

Indicated in mild knee arthrosis.

CE marking. ON: 0318. Class III, barren.

COMPOSITION

Sodium hyaluronate (obtained from Streptoccoccus zooepidemicus through fermentation processes and subsequent purification), sodium chloride, disodic phosphate dodecahydrate, sodium hydroxide, hydrochloric acid, injection water.

Contains 49 mg of sodium hialuronate to a concentration of 10mg/ml in preloaded glass syringe, one-use sterile for intraarticular use;
- Sodium chloride 41.7 mg
- Disodic phosphate dodecahydrate 2,9 mg
- Sodium hydroxide c.s.p adjust pH
- Cloric acid c.s.p adjust pH if necessary
- Water for injection c.s.p 4.9 ml"

.

CONSERVATION AND DACITY

Maintain between 1 and 30°C. If this temperature cannot be guaranteed, keep in fridge. Protect from the light.

CONTRAINDICATIONS

The product is contraindicated in patients with hypersensitivity history to the product itself.

EMPLEMENTATION MODEL

A single administration is recommended. The administration should be performed in the intraarticular space of the joint of the affected knee.

And make a follow-up visit 6 months after treatment to assess if a dose of memory is needed.

Given the viscosity of the product it is recommended to use 21-23G needles

PRECAUTIONS AND WARNINGS

This product may worsen local inflammation in those patients with knee osteoarthritis who suffer from inflammation and stroke of the joint. Therefore, it is advisable to administer the product after such inflammation has been relieved.

Local pain may rarely occur after product management per se. To avoid pain after injection, it is recommended to keep at rest the place where the administration has been performed. The product must be injected exactly into the intraarticular space because otherwise it can cause pain.

This product should be administered with care in patients with hypersensitivity history to other medications and in patients with liver failure or alteration.

Older use: The product should be administered carefully, as these patients have their physiological functions generally reduced.
Use in children: Since the safety of this product has not been established in children, care should be given in these patients.
Use in pregnancy and breastfeeding: Although teratogenic effects have not been detected in animals, their safety in pregnant women has not been established, so it is recommended to administer the product carefully to pregnant women or who may be. Sodium hyaluronate is excreted in the breast milk of treated animals, so it is recommended to stop breastfeeding during treatment.

Contact with disinfectants such as quaternary amonium salts, including benzalconium chloride or chlorhexidine, should be avoided because their precipitation may occur

WARNING REACTIONS

Rarely some patients develop skin rashes, such as urticaria and prurito. In these cases, the administration should be deleted and the patient should be given appropriate treatment. Pain (usually transient after administration) and swelling at the injection site have been described very rarely. Patients may rarely complain of hydropes, redness, heat sensation and heaviness at the injection site. The appearance of shock has rarely been described, in which case the administration should be suspended, the patient should be closely monitored and the appropriate treatment provided.